Amyloidogenesis is neither accelerated nor enhanced by injections of preformed fibrils in mice transgenic for wild-type human transthyretin: The question of infectivity

Amyloid

Volumn 11, Issue 1, 2004, Pages 21-26

  Tagoe, Clement E ^a   French, David ^b   Gallo, Gloria ^a   Buxbaum, Joel N ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Amyloidogenesis; Seeding; Transgenic animals; Transthyretin

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A2; PREALBUMIN;

ANIMAL TISSUE; ARTICLE; INFECTION; MOUSE; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; SCRAPIE; SENESCENCE; TRANSGENIC MOUSE; WILD TYPE;

AGING; AMYLOIDOSIS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CONGO RED; HUMANS; MICE; PREALBUMIN; SERUM AMYLOID A PROTEIN;

EID: 2542432374     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.1080/13506120410001674982     Document Type: Article

References (24)

1. Buxbaum JN and Tagoe CE (2000). The genetics of the amyloidoses. Ann Rev Med 51, 543-569
2. Kelly JW (2000). Mechanisms of amyloidogenesis. Nat Struct Biol 7, 824-826
3. Come JH, Fraser PE and Lansbury PT, Jr. (1993). A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci USA 90, 5959-5963
4. Jarrett JT and Lansbury PT, Jr. (1993). Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie. Cell 73, 1055-1058
5. Prusiner SB (1998). Prions. Proc Natl Acad Sci USA 95, 13363-13383
6. Lundmark K, Westermark GT, Nystrom S, Murphy CL, Solomon A and Westermark P (2002). Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 99, 6979-6984
7. Ganowiak K, Hultman P, Engstrom U, Gustavsson A and Westermark P (1994). Fibrils from synthetic amyloid-related peptides enhance development of experimental AA amyloidosis in mice. Biochem Biophys Res Commun 199, 306-312
8. Mambule C, Ando Y, Anan I, Holmgren G, Sandgren O, Stigbrandt T, Tashima K and Suhr OB (2000). Enhancement of AA-amyloid formation in mice by transthyretin amyloid fragments and polyethylene glycol. Biochim Biophys Acta 1474, 331-336
9. Higuchi K, Kogishi K, Wang J, Chen X, Chiba T, Matsushita T, Hoshii Y, Kawano H, Ishihara T, Yokota T and Hosokawa M (1998). Fibrilization in mouse senile amyloidosis is fibril conformation- dependent. Lab Invest 78, 1535-1542
10. Elliott-Bryant R and Cathcart ES (1998). Amyloid enhancing factor and dietary transmission in accelerated amyloid A amyloidosis. Clin Immunol Immunopathol 88, 65-69
11. Xing Y, Nakamura A, Chiba T, Kogishi K, Matsushita T, Li F, Guo Z, Hosokawa M, Mori M and Higuchi K (2001). Transmission of mouse senile amyloidosis. Lab Invest 81, 493-499
12. Dima RI and Thirumalai D (2002). Exploring protein aggregation and self-propagation using lattice models: phase diagram and kinetics. Protein Sci 11, 1036-1049
13. Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G and Buxbaum J (2001). Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 81, 385-396
14. Gallo GR, Feiner HD, Chuba JV, Beneck D, Marion P and Cohen DH (1986). Characterization of tissue amyloid by immunofluorescence microscopy. Clin Immunol Immunopathol 39, 479-488
15. Lashuel HA, Wurth C, Woo L and Kelly JW (1999). The most pathogenic transthyretin variant, 155p, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38, 13560-13573
16. Colon W and Kelly JW (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660
17. Pras M, Schubert M, Zucker-Franklin D, Rimon A and Franklin EC (1968). The characterization of soluble amyloid prepared in water. J Clin Invest 47, 924-933
18. Harper JD and Lansbury PT, Jr. (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66, 385-407
19. Xing Y, Nakamura A, Korenaga T, Guo Z, Yao J, Fu X, Matsushita T, Kogish K, Hosokawa M, Kametani F, Mori M and Higuchi K (2002). Induction of protein conformational change in mouse senile amyloidosis. J Biol Chem 277, 33164-33169
20. Sigurdsson E, Wisniewski T and Frangione B (2002). Infectivity of amyloid diseases. Trends Mol Med 8, 411
21. Higuchi K, Kogishi K, Wang J, Xia C, Chiba T, Matsushita T and Hosokawa M (1997). Accumulation of proapolipoprotein a-ii in mouse senile amyloid fibrils. Biochem J 325 (Part 3), 653-659
22. Benson MD and Liepnieks JJ (2001). A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AAI gene. Genomics 72, 272-277
23. Safar JJ, Wang W, Padgett MP, Ceroni M, Piccardo P, Zopf D, Gajdusek DC and Gibbs CJ, Jr. (1990). Molecular mass, biochemical composition, and physicochemical behavior of the infectious form of the scrapie precursor protein monomer. Proc Natl Acad Sci USA 87, 6373-6377
24. Johan K, Westermark G, Engstrom U, Gustavsson A, Hultman P and Westermark P (1998). Acceleration of amyloid protein a amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci USA 95, 2558-2563